Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Haleon Plc for the month of March 2026, with a specific reporting date of March 2, 2026. Haleon is a global leader in consumer health, operating across six major categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. The company markets well-known brands including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on capital structure and voting rights rather than financial performance.
Material Changes and Capital Structure
The primary disclosure concerns the company's share capital as of February 28, 2026:
- Total Issued Shares: 8,952,353,648 ordinary shares of £0.01 each.
- Treasury Shares: 43,969,144 shares held as treasury stock.
- Voting Shares: 8,908,384,504 ordinary shares with voting rights.
This figure of 8,908,384,504 voting shares serves as the denominator for shareholders to calculate notifiable interests under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves as a regulatory update on share capital rather than a strategic or financial outlook report.
Investor Verification Checklist
- Verify the total number of voting shares (8,908,384,504) for compliance with disclosure thresholds.
- Confirm the number of treasury shares (43,969,144) held by the company.
- Review the company's annual Form 20-F for comprehensive financial performance data, as this 6-K does not contain financial statements.